credited.
27 scientific societies within the USA with the express mission to "advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy." Citing concern for decreasing research funding in the research system, they have produced a report, "Sustaining Discovery in Biological and Medical Sciences" (FASEB 2015) , to provide a basis for further discussion. As a means of facilitating that discussion, they have also provided a survey available here under "Submit your comments". Comments are due by March 10th 2015. Coverage of the report is sparse and mostly draws on a piece in ScienceInsider (Kaiser 2015) .
The report is broken down into several components. The first examines the need to maximize research funding through legal and political means: sustainable funding by Congress and smarter use of funds through reduced regulatory burden and revised deployment of available resources. The report then discusses revision of the grant system and the mechanisms that fund researchers. Finally the report addresses the need to improve the sustainability and structure of the workforce, and discusses the need for adequate training of that workforce.
The report discusses background information, drawing heavily on previous reports such as the NIH Biomedical Working Group Report (NIH 2012) , before providing its own set of recommendations.
POINTS FOR DISCUSSION

THE REQUIREMENT FOR FEDERAL FUNDING
The FASEB report identifies key benefits of stable, long-term federal funding as opposed to philanthropic and industrial funding. First, it demonstrates that recent increases in non-federal funding sources fail to replace losses in federal funding. Furthermore, the report argues that there is a philosophical problem with relying on philanthropic and industrial funding: translational research may always be more attractive than basic research because short-term gains are obvious. Of course, basic science is important for drug discovery (Silber 2010) and education in clinical diagnosis (Woods et al. 2006) . Without federal support, this foundational research may be neglected. For this reason, there was even some discussion at the Future of Research Symposium (futureofresearch.org, (McDowell et al. 2014) ) that the NIH should focus on basic science, relying on partnership with industry for shortterm translational research. To justify the benefit of basic research, the FASEB report recommends a greater role for scientists in explaining the reasons for and roles of federal funding of science. This includes greater communication between scientists and their elected representatives. The academic community does very well at publishing academic papers, but not so well in sharing these results with the public bodies and elected officials that should hear about them.
CAREER OUTCOMES, AND REDUCING THE NUMBER OF TRAINEES
The report recommends increased transparency in career outcomes and prospects, which is data that has so far been severely lacking (see The Postdoctoral Experience Revisited, (NAP 2014) and which has also been called for elsewhere (McDowell et al. 2014, Polka, Krukenberg, and McDowell 2015) . The report also calls for changes to the academic culture of expecting all ECRs to aim for tenure-track faculty positions; therefore, it suggests that training in non-academic career paths be offered. This in turn raises questions about who will be responsible for carrying out this training, and how time out of the lab for training can be secured for ECRs. The report also explains (on p48, (FASEB 2015) ), "The most recent Survey of Doctorate Recipients documents a rise in the unemployment rate of recent biomedical PhD graduates (4.7 percent unemployment in 2012)…While this was below the national average in that year (8.1 percent), it was higher than the rate for all adults 25 years or older with at least a bachelor's degree (4.0 percent)." Having a PhD in biomedical science has now become less employable than remaining at a Bachelors' degree level.
This report fails to address, like so many others, the number of ECRs in the system. Despite the fact that the excess supply of PhDs is the root cause of many of the symptoms of the workforce issue, this point is consistently avoided, to the detriment of the discussion. The system cannot continue as it is with the same number of postgraduate students and postdoctoral researchers being directed towards tenure-track faculty positions. In our opinion, either we must change what the postdoc is for and allow postdocs to train for non-academic careers, or we keep the definition of a postdoc as a research post on the way to a faculty position, and drastically reduce the number of postdoctoral researchers, instead replacing them with staff scientists. The reason this is not proposed in the FASEB report, or indeed in many other proposals by societies and institutions, is because of the great cost to the system in paying staff rather than making use of an ill-defined workforce of "trainees." The senior scientific community's silence on this issue speaks volumes to the community of ECRs.
THE REQUIREMENT FOR PHYSICIANS
The report highlights the declining number of physician scientists; in particular, the fact that fewer medical students consider research careers in bench science and undertake postdoctoral training, and that fewer physicians are reporting research as their primary activity. This leads to the recommendation that salary caps should be raised (and new funding mechanisms introduced) to incentivize the movement of physicians into research.
Therefore, not only does the report resolutely fail to address the numbers of ECRs in the already overloaded pool, it actually proposes the addition of more competition. It does not address the possibility of mechanisms to increase collaboration between clinical practitioners and academic researchers, but rather suggests that medical students and physicians should be directed into the research pool themselves. For one thing, they rightly allude to the fact that "physician scientists…frequently receive higher remuneration from clinical services than research" and with the ever-increasing cost of already expensive medical education, there is of course less incentive for medical students to enter the competitive research environment when they are already in effect guaranteed jobs in clinical environments (certainly at a level higher than the 10% that PhDs can expect in attaining tenured faculty positions (Sauermann and Roach 2012) ) and despite concerns about the shortage of physicians in clinical settings, particularly in primary care (AAMC 2012). That physician scientists are singled out in this report for particular mention and a call for increasing numbers, without also addressing the numbers of ECRs already competing in the pool, is incongruous at best. Furthermore, it is interesting to consider that the word "diversity" appears twice in the entire document, with a two-sentence recommendation considering diversification of the workforce (Recommendation 3.4, (FASEB 2015)), despite the detrimental effect the current system has on career aspirations in under-represented minorities (Gibbs et al. 2014) . The issue of physician scientists, in contrast, occupies 3 pages and 2 recommendations (Recommendations 3.5 and 3.6, (FASEB 2015) ).
TRANSITION AWARDS FOR SENIOR INVESTIGATORS
Perhaps not coincidentally (see below) there is a call for the introduction of transition awards to essentially allow senior investigators to wind down their labs and collaborate with younger scientists. Thoughts on this will appear below, but we highlight this as a point on which action is actually being taken.
NIH EMERITUS AWARD: BACKGROUND, RESOURCES AND COMMENTING
The NIH has issued a Request for Information (NOT-OD-15-064) (NIH 2015) looking for responses by March 6th on a proposal for an "emeritus award" that allows senior investigators to transition out of running a lab and perhaps pass the projects to a junior investigator. This proposal has met with some controversy. There is more information on Sally Rockey's "Rock Talk" blog post, "Seeking Your Input on Sustaining the Workforce Through an Emeritus Award" (Rockey 2015) and we particularly recommend reading the comments section. For further thoughts on this proposal, you can also read the ever-thoughtful Jeremy Berg Datahound post (Berg 2015) and (from a more biased perspective) this commentary by Drugmonkey (Drugmonkey 2015) . The proposal has also received press coverage in Nature (Deng 2015) . These pieces provide interesting reading and point also to other sources.
Responses can be submitted electronically here.
POINTS FOR DISCUSSION
NOT GETTING THE MESSAGE?
Perhaps the most telling part of the Request for Information is that public comment is sought for "Impediments to the participation in such an award program, from the perspectives of both senior investigators and institutions." The fact that there is no mention of junior investigators, and that this is a proposal that NIH has chosen to focus on most urgently, is concerning.
There is much anger within the community (see above) at the thought that money for R01s (the principal major grant funding mechanism in the NIH) could be lost to increase funding specifically for senior investigators; an argument could be made that these are the last people who need additional funding. In particular, there has been some comment that it is already possible to transfer an R01 grant to another person, so this mechanism may, in effect, already exist.
In our opinion, the NIH needs to make a compelling argument for why this mechanism is needed. How will this benefit the members of the emeritus awardee's lab, or the junior investigator potentially receiving the lab after the transition? Is the goal to encourage earlier retirement by specifying a hard deadline for retirement after receiving the award? Is the goal to ease the transition out of the lab for the post-docs and grad students that need to find new labs?
We believe there is also an implication that junior investigators require the benevolent passing of project ideas from more senior investigators, rather than having their own independent projects, and indeed a recent report by Ewan Callaway in Nature has highlighted that, in fact, younger investigators may be considered more innovative than senior researchers, by some metrics (Callaway 2015) . Some comments on the Rock Talk blog suggest that making the project focused on the junior faculty by giving them full control over the budget could ameliorate the concern; the senior investigator could be involved with the goal of transferring equipment and of course collaborative expertise.
On the other hand, it is encouraging to see the NIH thinking of creative funding mechanisms rather than a reliance purely on the R01-like mechanisms. Discussions are needed on the various ways of making use of talent in science in particular with a system that has a much higher number of "trainees" than permanent academic positions for them to eventually take. In particular, the discussion of methods to share resources and people across lab boundaries is likely to encourage greater collaboration. But if the NIH truly wants to make the best use of the current pool of scientific talent, then we believe that such awards as this, which will only affect a very small portion of the talent pool, should not be their major focus and instead they should look at mechanisms to prevent talented scientists from being forced out of academia at the ECR and junior faculty levels.
The NIH certainly can't be faulted for provoking debate. The only ones at fault will be those who don't take the opportunity to comment. This is not the only means of taking action to change the biomedical research system; we cannot allow anyone to think "no news is good news." If ECRs aren't contributing to the ongoing conversations and making their concerns heard, it is much harder to make progress. In the hope that this has provoked some debate and dialogue, we encourage you to take the opportunity to comment on these proposals.
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